122 related articles for article (PubMed ID: 1822001)
21. Doxorubicin selected multidrug-resistant small cell lung cancer cell lines characterised by elevated cytoplasmic Ca2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression.
Nygren P; Larsson R; Gruber A; Peterson C; Bergh J
Br J Cancer; 1991 Dec; 64(6):1011-8. PubMed ID: 1684906
[TBL] [Abstract][Full Text] [Related]
22. In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin.
Tanaka M; Grossman HB
Gene Ther; 2003 Sep; 10(19):1636-42. PubMed ID: 12923562
[TBL] [Abstract][Full Text] [Related]
23. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
Zhang ZL; Jiang QC; Wang SR
Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
[TBL] [Abstract][Full Text] [Related]
24. Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells.
Tapiero H; Nguyen-Ba G; Lampidis TJ
Pathol Biol (Paris); 1994 Apr; 42(4):328-37. PubMed ID: 7808786
[TBL] [Abstract][Full Text] [Related]
25. Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage.
Bellamy WT; Dalton WS; Kailey JM; Gleason MC; McCloskey TM; Dorr RT; Alberts DS
Cancer Res; 1988 Nov; 48(22):6365-70. PubMed ID: 3180056
[TBL] [Abstract][Full Text] [Related]
26. Relationship between cytotoxicity, drug accumulation, DNA damage and repair of human ovarian cancer cells treated with doxorubicin: modulation by the tiapamil analog RO11-2933.
Alaoui Jamali MA; Yin MB; Mazzoni A; Bankusli I; Rustum YM
Cancer Chemother Pharmacol; 1989; 25(2):77-83. PubMed ID: 2598402
[TBL] [Abstract][Full Text] [Related]
27. Does P-glycoprotein play a pivotal role in the drug resistance of an MDR variant, K562/Dox?
Hu X; Yang H; Pan QR; Zheng S
Chemotherapy; 1995; 41(4):296-305. PubMed ID: 7555211
[TBL] [Abstract][Full Text] [Related]
28. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells.
Nagasawa K; Natazuka T; Chihara K; Kitazawa F; Tsumura A; Takara K; Nomiyama M; Ohnishi N; Yokoyama T
Cancer Chemother Pharmacol; 1996; 37(4):297-304. PubMed ID: 8548874
[TBL] [Abstract][Full Text] [Related]
29. 2-Pyrrolinodoxorubicin and its peptide-vectorized form bypass multidrug resistance.
Castex C; Merida P; Blanc E; Clair P; Rees AR; Temsamani J
Anticancer Drugs; 2004 Jul; 15(6):609-17. PubMed ID: 15205606
[TBL] [Abstract][Full Text] [Related]
30. Modulatory effects of tamoxifen and recombinant human alpha-interferon on doxorubicin resistance.
Kang Y; Perry RR
Cancer Res; 1993 Jul; 53(13):3040-5. PubMed ID: 8100483
[TBL] [Abstract][Full Text] [Related]
31. Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity.
Tang J; Zhang L; Gao H; Liu Y; Zhang Q; Ran R; Zhang Z; He Q
Drug Deliv; 2016 May; 23(4):1130-43. PubMed ID: 25491241
[TBL] [Abstract][Full Text] [Related]
32. P-glycoprotein-mediated efflux of hydroxyrubicin, a neutral anthracycline derivative, in resistant K562 cells.
Borrel MN; Fiallo M; Priebe W; Garnier-Suillerot A
FEBS Lett; 1994 Dec; 356(2-3):287-99. PubMed ID: 7805856
[TBL] [Abstract][Full Text] [Related]
33. P-glycoprotein and alterations in the glutathione/glutathione-peroxidase cycle underlie doxorubicin resistance in HL-60-R, a subclone of the HL-60 human leukemia cell line.
Raghu G; Pierre-Jerome M; Dordal MS; Simonian P; Bauer KD; Winter JN
Int J Cancer; 1993 Mar; 53(5):804-11. PubMed ID: 8095491
[TBL] [Abstract][Full Text] [Related]
34. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
35. Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells.
Schuurhuis GJ; van Heijningen TH; Cervantes A; Pinedo HM; de Lange JH; Keizer HG; Broxterman HJ; Baak JP; Lankelma J
Br J Cancer; 1993 Nov; 68(5):898-908. PubMed ID: 8105865
[TBL] [Abstract][Full Text] [Related]
36. [Effect of quinine on the multiple drug resistance and intracellular distribution of pirarubicin in LR73 tumor cells: a comparative study with verapamil and S9788 by confocal laser microspectrofluorometry].
Belhoussine R; Morjani H; Manfait M
Bull Cancer; 1997 Apr; 84(4):343-9. PubMed ID: 9238156
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro.
Bazargan L; Fouladdel S; Shafiee A; Amini M; Ghaffari SM; Azizi E
Cell Biol Toxicol; 2008 Apr; 24(2):165-74. PubMed ID: 17805981
[TBL] [Abstract][Full Text] [Related]
38. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
[TBL] [Abstract][Full Text] [Related]
39. The efflux of anthracyclines in multidrug-resistant cell lines.
Coley HM; Twentyman PR; Workman P
Biochem Pharmacol; 1993 Oct; 46(8):1317-26. PubMed ID: 7902089
[TBL] [Abstract][Full Text] [Related]
40. Doxorubicin cellular pharmacokinetics plays no role in chemosensitizing effect of verapamil on Swiss-3T3 cells.
Wang N; Tang ZM; Zhang YP; Ding QM
Zhongguo Yao Li Xue Bao; 1996 Sep; 17(5):402-6. PubMed ID: 9863159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
